Table 1. Selected demographic and clinical characteristics by prediagnosis BMI in KP-ROCS study (2000–2014).
|
No. (row %) of participants by prediagnosis BMI (kg m−2) |
|||||||
|---|---|---|---|---|---|---|---|
| No. (col %) of overall cohorta 1157 (100) | 18.5–24.99 355 (30.7) | 25–29.99 383 (33.1) | 30–34.99 218 (18.8) | 35–39.99 106 (9.2) | ⩾40 95 (8.2) | P-valueb | |
|
Age at diagnosis (years) | |||||||
| 21–39 | 36 (3.1) | 14 (38.9) | 7 (19.4) | 4 (11.1) | 4 (11.1) | 7 (19.4) | 0.02 |
| 40–49 | 139 (12.0) | 45 (32.4) | 42 (30.2) | 29 (20.9) | 14 (10.1) | 9 (6.5) | |
| 50–69 | 631 (54.5) | 184 (29.2) | 201 (31.9) | 124 (19.7) | 59 (9.4) | 63 (10.0) | |
| ⩾70 | 351 (30.3) | 112 (31.9) | 133 (37.9) | 61 (17.4) | 29 (8.3) | 16 (4.6) | |
| Mean±s.d. | 62.6±12.6 | 62.8±13.4 | 63.7±12.4 | 62.5±12.0 | 61.5±12.2 | 58.2±11.4 | 0.003 |
|
Race/ethnicity | |||||||
| White | 802 (69.3) | 256 (31.9) | 254 (31.7) | 147 (18.3) | 76 (9.5) | 69 (8.6) | <0.001 |
| African American | 77 (6.7) | 7 (9.1) | 20 (26.0) | 22 (28.6) | 15 (19.5) | 13 (16.9) | |
| Hispanic | 111 (9.6) | 12 (10.8) | 47 (42.3) | 34 (30.6) | 12 (10.8) | 6 (5.4) | |
| Asian | 146 (12.6) | 71 (48.6) | 59 (40.4) | 11 (7.5) | 2 (1.4) | 3 (2.1) | |
| Other | 21 (1.8) | 9 (42.9) | 3 (14.3) | 4 (19.1) | 1 (4.8) | 4 (19.1) | |
|
BMI at diagnosis (kg m−2) | |||||||
| Normal (18.5–24.99) | 401 (34.7) | 323 (80.6) | 72 (18.0) | 5 (1.3) | 1 (0.3) | 0 (0.0) | <0.001 |
| Overweight (25–29.99) | 374 (32.3) | 32 (8.6) | 273 (73.0) | 66 (17.7) | 2 (0.5) | 1 (0.3) | |
| Obese I (30–34.99) | 201 (17.4) | 0 (0.0) | 35 (17.4) | 130 (64.7) | 32 (15.9) | 4 (2.0) | |
| Obese II (35–39.99) | 105 (9.1) | 0 (0.0) | 3 (2.9) | 16 (15.2) | 63 (60.0) | 23 (21.9) | |
| Obese III (⩾40) | 76 (6.6) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 8 (10.5) | 67 (88.2) | |
|
AJCC stage | |||||||
| I | 248 (21.4) | 80 (32.3) | 78 (31.5) | 47 (19.0) | 21 (8.5) | 22 (8.9) | 0.96 |
| II | 93 (8.0) | 27 (29.0) | 31 (33.3) | 19 (20.4) | 6 (6.5) | 10 (10.8) | |
| III | 493 (42.6) | 149 (30.2) | 159 (32.3) | 94 (19.1) | 55 (11.2) | 36 (7.3) | |
| IV | 305 (26.4) | 94 (30.8) | 108 (35.4) | 55 (18.0) | 22 (7.2) | 26 (8.5) | |
| Unknown | 18 (1.6) | 5 (27.8) | 7 (38.9) | 3 (16.7) | 2 (11.1) | 1 (5.6) | |
|
Grade (SEER definition) | |||||||
| Well differentiated | 78 (6.7) | 23 (29.5) | 28 (35.9) | 11 (14.1) | 6 (7.7) | 10 (12.8) | 0.71 |
| Moderately differentiated | 125 (10.8) | 37 (29.6) | 46 (36.8) | 20 (16.0) | 11 (8.8) | 11 (8.8) | |
| Poorly differentiated | 387 (33.5) | 118 (30.5) | 131 (33.9) | 79 (20.4) | 31 (8.0) | 28 (7.2) | |
| Undifferentiated | 228 (19.7) | 76 (33.3) | 74 (32.5) | 46 (20.2) | 19 (8.3) | 13 (5.7) | |
| Unknown | 339 (29.3) | 101 (29.8) | 104 (30.7) | 62 (18.3) | 39 (11.5) | 33 (9.7) | |
|
Histology | |||||||
| Serous | 629 (54.4) | 203 (32.3) | 203 (32.3) | 126 (20.0) | 65 (10.3) | 32 (5.1) | 0.006 |
| Mucinous | 54 (4.7) | 18 (33.3) | 19 (35.2) | 7 (13.0) | 2 (3.7) | 8 (14.8) | |
| Endometrioid | 115 (9.9) | 27 (23.5) | 38 (33.0) | 21 (18.3) | 8 (7.0) | 21 (18.3) | |
| Clear cell | 84 (7.3) | 27 (32.1) | 27 (32.1) | 16 (19.1) | 7 (8.3) | 7 (8.3) | |
| Other | 275 (23.8) | 80 (29.1) | 96 (34.9) | 48 (17.5) | 24 (8.7) | 27 (9.8) | |
|
Ascites at diagnosis | |||||||
| No | 770 (66.6) | 106 (27.4) | 120 (31.0) | 81 (20.9) | 43 (11.1) | 37 (9.6) | 0.10 |
| Yes | 387 (33.5) | 249 (32.3) | 263 (34.2) | 137 (17.8) | 63 (8.2) | 58 (7.5) | |
|
Ascitesc | |||||||
| No | 612 (52.9) | 200 (32.7) | 201 (32.8) | 113 (18.5) | 51 (8.3) | 47 (7.7) | 0.52 |
| Yes | 545 (47.1) | 155 (28.4) | 182 (33.4) | 105 (19.3) | 55 (10.1) | 48 (8.8) | |
|
Bowel obstructionc | |||||||
| No | 745 (64.4) | 237 (31.8) | 250 (33.6) | 127 (17.1) | 66 (8.9) | 65 (8.7) | 0.24 |
| Yes | 412 (35.6) | 118 (28.6) | 133 (32.3) | 91 (22.1) | 40 (9.7) | 30 (7.3) | |
|
Cachexiac | |||||||
| No | 1075 (92.9) | 312 (29.0) | 360 (33.5) | 211 (19.6) | 99 (9.2) | 93 (8.7) | <0.001 |
| Yes | 82 (7.1) | 43 (52.4) | 23 (28.1) | 7 (8.5) | 7 (8.5) | 2 (2.4) | |
|
Chemotherapy | |||||||
| No | 187 (16.2) | 59 (31.6) | 62 (33.2) | 35 (18.7) | 15 (8.0) | 16 (8.6) | 0.86 |
| Yes, carboplatin+paclitaxel | 524 (45.3) | 155 (29.6) | 176 (33.6) | 107 (20.4) | 43 (8.2) | 43 (8.2) | |
| Yes, other regimen | 446 (38.6) | 141 (31.6) | 145 (32.5) | 76 (17.0) | 48 (10.8) | 36 (8.1) | |
|
Surgery | |||||||
| No | 70 (6.1) | 23 (32.9) | 20 (28.6) | 12 (17.1) | 8 (11.4) | 7 (10.0) | 0.84 |
| Yes | 1087 (94.0) | 332 (30.5) | 363 (33.4) | 206 (19.0) | 98 (9.0) | 88 (8.1) | |
|
CA125 (U ml−1) | |||||||
| <35 | 764 (66.0) | 245 (32.1) | 251 (32.9) | 145 (19.0) | 65 (8.5) | 58 (7.6) | 0.53 |
| 35–70 | 72 (6.2) | 28 (38.9) | 21 (29.2) | 10 (13.9) | 8 (11.1) | 5 (6.9) | |
| >70 | 204 (17.6) | 55 (27.0) | 66 (32.4) | 39 (19.1) | 23 (11.3) | 21 (10.3) | |
| Unknown | 117 (10.1) | 27 (23.1) | 45 (38.5) | 24 (20.5) | 10 (8.5) | 11 (9.4) | |
|
Comorbidities | |||||||
| Diabetes, type 2 | |||||||
| No | 896 (77.4) | 318 (35.5) | 308 (34.4) | 154 (17.2) | 67 (7.5) | 49 (5.5) | <0.001 |
| Yes | 261 (22.6) | 37 (14.2) | 75 (28.7) | 64 (24.5) | 39 (14.9) | 46 (17.6) | |
| Hypertension | |||||||
| No | 418 (36.1) | 183 (43.8) | 136 (32.5) | 56 (13.4) | 29 (6.9) | 14 (3.4) | <0.001 |
| Yes | 739 (63.9) | 172 (23.3) | 247 (33.4) | 162 (21.9) | 77 (10.4) | 81 (11.0) | |
| CVD | |||||||
| No | 479 (41.4) | 160 (33.4) | 157 (32.8) | 83 (17.3) | 37 (7.7) | 42 (8.8) | 0.27 |
| Yes | 678 (58.6) | 195 (28.8) | 226 (33.3) | 135 (19.9) | 69 (10.2) | 53 (7.8) | |
| Renal insufficiency | |||||||
| No | 737 (63.7) | 258 (35.0) | 248 (33.7) | 134 (18.2) | 58 (7.9) | 39 (5.3) | <0.001 |
| Yes | 420 (36.3) | 97 (23.1) | 135 (32.1) | 84 (20.0) | 48 (11.4) | 56 (13.3) | |
Abbreviations: AJCC=American Joint Committee on Cancer; ANOVA=analysis of variance; BMI=body mass index; CA125=cancer antigen 125; CVD=cardiovascular disease; KP-ROCS=Kaiser Permanente Research on Ovarian Cancer Survival; SEER=Surveillance, Epidemiology, and End Results.
a
A total of 27 underweight women (n=10 for ‘prediagnosis’, n=21 for ‘at diagnosis’, and n=4 in both periods) were excluded.
b
Based on χ2 test, Fisher’s Exact text, or ANOVA, as appropriate.
c
Three years before diagnosis to end of follow-up.